Advertisement

Topics

Poxel SAS Company Profile

00:43 EST 22nd November 2017 | BioPortfolio

Poxel is a new RIPCO that aims to advance promising assets for cardio-metabolic diseases from Research to Phase 2 Clinical Proof of Concept, before out licensing projects to pharmaceutical companies. Poxel will further develop its portfolio by considering all opportunities corresponding to its core domain of competencies.


News Articles [31 Associated News Articles listed on BioPortfolio]

Sumitomo Dainippon Acquires Asian Rights to Poxel's Diabetes Drug in $300 Million Agreement

Japan's Sumitomo Dainippon Pharma announced a $300 million deal to develop Poxel's novel type 2 diabetes treatment in Japan, China and eleven other SE Asian countries. Poxel, a French biopharma, has c...

Poxel to Present Results for Imeglimin Phase 2b Study in Japan for the Treatment of Type 2 Diabetes at the European Association for the Study of Diabetes 53rd Annual Meeting

Wednesday, September 6th 2017 at 6:00am UTC Lyon, FRANCE–(BUSINESS WIRE)– POXEL SA (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on the development of inno...

Poxel Presents New Preclinical Imeglimin Data Demonstrating Improvement of Both Peripheral and Coronary Vascular Function at the European Society of Cardiology Congress

Monday, August 28th 2017 at 6:00am UTC Additional data from metabolic syndrome model support protective effects of Imeglimin on diabetic cardiomyopathy, a significant cardiovascular complication in di...

Poxel Announces Participation at the Jefferies 2017 London Healthcare Conference

POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes,...

Poxel grants Sumitomo Asian rights to type 2 diabetes drug

Sumitomo Dainippon Pharma has gained rights to Poxel's type 2 diabetes drug PXL008, or imeglimin, in China, Japan, Taiwan, So -More- 

Sumitomo Dainippon gets rights to Poxel's imeglimin in thirteen Asian countries

Poxel SA licensed Sumitomo Dainippon Pharma Co. Ltd. rights to develop and commercialize its Phase II Type II diabetes candidate imeglimin in Japan, China, South Korea, Taiwan, Indonesia, Vietnam, Tha...

MERCK SANTÉ SAS: MERCK ANNOUNCES SALE OF POXEL EQUITY STAKE

MERCK SANTÉ SAS / MERCK ANNOUNCES SALE OF POXEL EQUITY STAKE . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Press .....

Sumitomo gains Asian rights to Poxel's imeglimin

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Poxel SAS

Poxel is a new RIPCO that aims to advance promising assets for cardio-metabolic diseases from Research to Phase 2 Clinical Proof of Concept, before out licensing projects to pharmaceutical compani...

More Information about "Poxel SAS" on BioPortfolio

We have published hundreds of Poxel SAS news stories on BioPortfolio along with dozens of Poxel SAS Clinical Trials and PubMed Articles about Poxel SAS for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Poxel SAS Companies in our database. You can also find out about relevant Poxel SAS Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...


Corporate Database Quicklinks



Searches Linking to this Company Record